<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-144967" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Aflibercept</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Adams</surname>
            <given-names>Bryan S.</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sorhaitz</surname>
            <given-names>Winston</given-names>
          </name>
          <aff>Kansas City University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stringham</surname>
            <given-names>Jack</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bryan Adams declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Winston Sorhaitz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jack Stringham declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-144967.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy. It is in the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonist class of medications. Aflibercept acts as a soluble protein decoy for VEGF receptors to inhibit the predominant signaling pathway responsible for angiogenesis and vascular leakage. Aflibercept and other anti-VEGF inhibitors have become the gold standard in controlling neovascular (wet) age-related macular degeneration (NVAMD). This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in managing patients with exudative retinal diseases.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the approved indications of aflibercept.</p></list-item><list-item><p>Summarize the mechanism of action of aflibercept.</p></list-item><list-item><p>Outline interprofessional team strategies for improving the use of aflibercept.</p></list-item><list-item><p>Review the most common adverse events associated with aflibercept therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144967&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144967">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-144967.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Aflibercept is a humanized recombinant fusion protein that functions as a vascular endothelial growth factor (VEGF) inhibitor, thus preventing choroidal neovascularization. The VEGF signaling pathway is implicated in the induction of gene expression, regulation of vascular permeability, proliferation, and survival.<bold>&#x000a0;</bold></p>
        <p>Studies demonstrate increased levels of VEGF-A in the aqueous and vitreous fluid of eyes with diabetic macular edema and proliferative diabetic retinopathy. Aflibercept was first FDA-approved in 2011 for neovascular (wet) age-related macular degeneration (NVAMD).<xref ref-type="bibr" rid="article-144967.r1">[1]</xref>&#x000a0;</p>
        <p>Since then, additional FDA approval has been granted for macular edema associated with retinal vein occlusion (RVO), diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and diabetic retinopathy (DR).<xref ref-type="bibr" rid="article-144967.r2">[2]</xref><xref ref-type="bibr" rid="article-144967.r3">[3]</xref><xref ref-type="bibr" rid="article-144967.r4">[4]</xref></p>
      </sec>
      <sec id="article-144967.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Aflibercept is a dimeric glycoprotein (molecular weight= 115 kDa) that acts as a soluble protein decoy for VEGF receptors (VEGFR-1 and VEGFR-2) present on the surface of endothelial cells in the retina.<xref ref-type="bibr" rid="article-144967.r5">[5]</xref>&#x000a0;Aflibercept preferentially binds to VEGF-A and PIGF with a much greater affinity than its natural angiogenic competitors (VEGFR-1 and VEGFR-2).</p>
        <p>Through this mechanism, aflibercept prevents ligand-induced dimerization of VEGFR-2, preventing downstream activation of the intracellular tyrosine kinase domains from inhibiting pathologic angiogenesis.</p>
        <p>Aflibercept exerts its inhibitory effects on VEGF receptors preventing endothelial proliferation, vascular permeability, and neovascularization. This targeted intravitreal injection therapy aims to inhibit VEGF signaling, which underlies angiogenesis and vascular leak characteristic of NVAMD.<xref ref-type="bibr" rid="article-144967.r6">[6]</xref></p>
        <p>Compared to other VEGF inhibitors, aflibercept is thought to have at least a 200-fold higher affinity for VEGF, which explains optimal therapeutic outcomes of patients receiving intravitreal aflibercept therapy. In addition, the relatively small molecular size of aflibercept allows for enhanced diffusion into the retina and choroid.<xref ref-type="bibr" rid="article-144967.r7">[7]</xref></p>
      </sec>
      <sec id="article-144967.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Aflibercept is delivered as an intravitreal injection into the affected eye. Aflibercept is a colorless solution that comes packaged in prefilled syringes. It must be stored in a refrigerator for extended periods but can be kept at room temperature for less than 24 hours. Clinicians should practice proper sterile surgical procedures when delivering any intravitreal injection.</p>
        <p>According to the initial FDA approval dosage and administration, the recommended dose for aflibercept is 2 mg (0.05 mL) administered by intravitreal injection every four weeks (monthly) for the first three months, followed by 2 mg (0.05 mL) once every eight weeks (two months).<xref ref-type="bibr" rid="article-144967.r8">[8]</xref></p>
        <p>Landmark trials have established the benefit of the Treat-and-Extend regimen (TAE) compared to fixed dosing, which involves fewer injections and visits in total and superior outcomes. This regimen, which has become standard of care, involves aflibercept injections based on response to treatment. Treat-and-extend dosing regimens minimize the risk of recurrence of submacular edema and reduce capacity-planning in AMD services and treatment delays.<xref ref-type="bibr" rid="article-144967.r9">[9]</xref>&#x000a0;</p>
        <p>Understanding administration guidelines and following a strict, standardized protocol is essential to avoid severe complications of intravitreal aflibercept administration such as endophthalmitis, retinal tear, retinal detachment, and lens injury.<xref ref-type="bibr" rid="article-144967.r10">[10]</xref>&#x000a0;The standard antiseptic protocol includes hand disinfection, sterile gloves, a sterile speculum, and topical microbicide solution on the eye.<xref ref-type="bibr" rid="article-144967.r11">[11]</xref></p>
        <p>
<bold>Injection Protocol</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>First, the patient is placed in a comfortable, supine position.</p>
          </list-item>
          <list-item>
            <p>Lids, lashes, and surrounding skin are sterilized with 10% povidone-iodine.</p>
          </list-item>
          <list-item>
            <p>Several drops of Proparacaine Hydrochloride are instilled in the conjunctival cul-de-sac.</p>
          </list-item>
          <list-item>
            <p>Following the instillation of povidone-iodine and proparacaine drops, a speculum is inserted in the eye.</p>
          </list-item>
          <list-item>
            <p>Then, the physician determines the injection site by measuring 3.5&#x000a0;to 4 millimeters posterior to the limbus in the superotemporal quadrant. Accurate measurement from the limbus is critical to prevent lens damage in phakic patients. Additionally, superior temporal intravitreal injection is generally preferred to avoid iatrogenic inferior retinal detachment.</p>
          </list-item>
          <list-item>
            <p>The patient is instructed to look in a particular direction depending on the injection site.</p>
          </list-item>
          <list-item>
            <p>The medication is injected gently through pars plana.</p>
          </list-item>
          <list-item>
            <p>After injection, the speculum is removed, and the eye is washed with a basic saline solution.<xref ref-type="bibr" rid="article-144967.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-144967.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects associated with aflibercept use include eye irritation, vitreous detachment, temporary blurred vision, eyelid swelling, and conjunctival hemorrhage. Serious adverse reactions related to the administration of aflibercept and the injection procedure include retinal detachment, traumatic cataracts, thromboembolic events, and increased intraocular pressure (IOP). These complications are observed in less than 0.1% of intravitreal injections with aflibercept.<xref ref-type="bibr" rid="article-144967.r13">[13]</xref></p>
        <p>A temporary rise in intraocular pressure within 60 minutes of administration&#x000a0;can be expected and should return to baseline in minutes following injection. Intraocular pressure may take longer to normalize in patients with glaucoma and other ocular comorbidities. Patients should be educated about common and severe adverse effects and know when to notify their doctor.<xref ref-type="bibr" rid="article-144967.r14">[14]</xref></p>
      </sec>
      <sec id="article-144967.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to intravitreal aflibercept include ocular or periocular infections, active ocular inflammation, and known hypersensitivity to aflibercept or any excipients found in the formulation. Patients should be counseled on the common symptoms of hypersensitivity reactions, including rash, urticaria, pruritus, severe ocular intraocular inflammation, or severe anaphylactic reactions. Patients who have an ocular infection, have recently undergone ocular surgery, or have increased intraocular pressure should avoid intravitreal aflibercept use.<xref ref-type="bibr" rid="article-144967.r15">[15]</xref></p>
        <p>There is no data on the effects of intravitreal aflibercept on human fertility. Data in primate studies showed reversibly impaired fertility and function in female reproductive systems at intravenous administration doses 1500 times higher than the human systemic level. As such, the FDA has recommended effective contraception in reproductive-aged females before, during treatment, and at least three months following the last intravitreal injection of aflibercept.<xref ref-type="bibr" rid="article-144967.r16">[16]</xref></p>
        <p>Aflibercept is not recommended while breastfeeding due to the potential for drug excretion in breast milk and the threat to infant growth and development. Studies have not yet established the safety and effectiveness of aflibercept in pediatric patients.<xref ref-type="bibr" rid="article-144967.r17">[17]</xref></p>
      </sec>
      <sec id="article-144967.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Following aflibercept administration, patient self-monitoring is essential to detect signs of infection, pain,&#x000a0;and/or decreased visual acuity. Patients should be instructed on Amsler grid use to monitor reactivation of Neovascular age-related macular degeneration (NVAMD). Severe complications such as endophthalmitis, retinal detachment, and increased intraocular pressure (IOP) have been associated with intravitreal injection. Intraocular pressure should be monitored before and after intravitreal injection of aflibercept.<xref ref-type="bibr" rid="article-144967.r18">[18]</xref></p>
        <p>Overall systemic exposure is low due to rapid elimination after passing through the vitreous. No drug metabolism studies have been conducted. As a low-molecular-weight glycoprotein, aflibercept is believed to undergo proteolysis and elimination via target-mediated elimination by binding free endogenous VEGF. For a dose of 2 to 4 mg/kg, aflibercept has a half-life (t1/2) of approximately 5 to 6 days after 2 to 4 mg/kg intravitreal injection (IVI).<xref ref-type="bibr" rid="article-144967.r19">[19]</xref>&#x000a0;</p>
        <p>Few rare toxicities have been reported involving&#x000a0;minimal systemic absorption. Single case reports describe intravitreal aflibercept crossing the blood-retina barrier leading to vascular-related thromboembolism, heart attack, stroke, and even death.<xref ref-type="bibr" rid="article-144967.r20">[20]</xref></p>
        <p>Other case studies describe worsening of preexisting chronic kidney disease (CKD), acute interstitial nephritis (AIN) in the background of diabetic glomerulosclerosis, and focal and segmental glomerulosclerosis (FSGS). These are very rare but highlight the potential of deleterious systemic and renal pathological disorders in the setting of intravitreal VEGF blockade. Additionally, patients with macular ischemia should be carefully monitored when considering prolonged anti-VEGF therapy due to an already compromised blood supply.<xref ref-type="bibr" rid="article-144967.r21">[21]</xref></p>
        <p>Despite rarely observed adverse effects, aflibercept has a highly desirable therapeutic profile compared to other anti-VEGF analogs. Aflibercept use is associated with rapid visual improvement, less frequent need for subsequent injection therapy, and prolonged maintenance. Randomized clinical trials of intravitreal aflibercept administration demonstrate superior outcomes of eight-week dosing regimens compared to monthly dosing, resulting in an overall decreased frequency of injections.<xref ref-type="bibr" rid="article-144967.r22">[22]</xref></p>
      </sec>
      <sec id="article-144967.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Aflibercept is intended for intravitreal administration to exert local effects in the eye. IVI allows the medication to penetrate all retinal layers, minimizing systemic effects. No cytotoxic effects have been observed in studies that exposed cultured corneal endothelial cells to varying concentrations of aflibercept.<xref ref-type="bibr" rid="article-144967.r23">[23]</xref></p>
        <p>However, there has been an interest in the potential for drug overdose with intravitreal aflibercept therapy due to a slight misalignment of the plunger in prefilled syringes. These small mismeasurements can lead to delivering double the intended volume of medication. In part, aflibercept overdose accounts for a number of intraocular pressure elevations since its launch. Unfortunately, there is no known antidote for aflibercept overdose. Proper adherence to instructions for use can minimize dosing errors and prevent toxicity of intravitreal aflibercept.<xref ref-type="bibr" rid="article-144967.r24">[24]</xref></p>
      </sec>
      <sec id="article-144967.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Aflibercept is a humanized recombinant fusion protein designed for intraocular use. Intravitreal injection is indicated for the treatment of neovascular (wet) age-related macular degeneration (NVAMD), macular edema associated with retinal vein occlusion (RVO), diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and diabetic retinopathy.</p>
        <p>Proper diagnosis and management of ocular diseases can significantly impact a patient's quality of life. Managing the treatment of ocular disease with abnormal angiogenesis such as NVAMD and DR requires an interprofessional team of providers (physicians, including specialists, mid-level practitioners, nurses, and pharmacists) to ensure effective treatment.<xref ref-type="bibr" rid="article-144967.r2">[2]</xref><xref ref-type="bibr" rid="article-144967.r3">[3]</xref></p>
        <p>To ensure patient safety, specific roles of healthcare team members should be well-defined, and medical personnel should be well trained in their specific roles. The team members include healthcare practitioners, specialists, technicians, surgical assistants, and optometrists. Clinical ophthalmic technicians update patient history and test visual acuity and pressure before the patient sees the retinal specialist.</p>
        <p>Clinical technicians also obtain imaging studies, including optical coherence tomography (OCT) and fundus photography. OCT produces cross-sectional images of the retina to see different layers and evaluate disease progression and the effect of prior treatments. When therapy is indicated, ophthalmic technicians counsel patients on risks and benefits before obtaining consent for the procedure.</p>
        <p>At the time of the procedure, nurses review the timeout sheet, which should include the correct eye, procedure, and drug to be administered. Surgical assistants prepare the procedure tray, gown and drape the patient, clean and disinfect the injection site, and assist the clinician during administration. Specialists follow standardized protocol guidelines to ensure safe intravitreal aflibercept administration.</p>
        <p>Technicians may administer post-injection antibiotics, remove the patient's drape and wash the eye with a basic saline solution. Technicians provide post-injection care instructions and schedule return visits. Optometrists are crucial in closely monitoring response to aflibercept therapy at follow-up visits.<xref ref-type="bibr" rid="article-144967.r25">[25]</xref></p>
        <p>The patient should be educated and monitored for signs of elevated intraocular pressure. Patients should also be advised to call or return to the clinic if they begin to experience severe eye pain after receiving an injection. All team members must continue to monitor the patient as they have interactions with them, documenting their observations in the patient's medical record. If they note any concerns, including therapeutic failure or adverse events, they must immediately communicate these to the appropriate team members so additional evaluation can occur, potentially leading to corrective action.<xref ref-type="bibr" rid="article-144967.r18">[18]</xref></p>
        <p>Patient self-monitoring is crucial to detect signs of infection and decreased visual acuity.&#x000a0;An interprofessional team-based approach involving clinicians, specialists, optometrists, ophthalmic technicians, and patients leads to desired&#x000a0;therapeutic outcomes,&#x000a0;minimizes the risk of&#x000a0;disease&#x000a0;progression, and improves the quality of life.<xref ref-type="bibr" rid="article-144967.r18">[18]</xref> [Level 5]&#x000a0;</p>
      </sec>
      <sec id="article-144967.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144967&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144967">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/144967/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=144967">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-144967.s11">
        <title>References</title>
        <ref id="article-144967.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ba</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2015</year>
            <volume>9</volume>
            <fpage>5397</fpage>
            <page-range>5397-405</page-range>
            <pub-id pub-id-type="pmid">26451092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balaratnasingam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dhrami-Gavazi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McCann</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Ghadiali</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2015</year>
            <volume>9</volume>
            <fpage>2355</fpage>
            <page-range>2355-71</page-range>
            <pub-id pub-id-type="pmid">26719668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keating</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Aflibercept: A Review of Its Use in Diabetic Macular Oedema.</article-title>
            <source>Drugs</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>75</volume>
            <issue>10</issue>
            <fpage>1153</fpage>
            <page-range>1153-60</page-range>
            <pub-id pub-id-type="pmid">26056030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anguita</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tasiopoulou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shahid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Correction to: A Review of Aflibercept Treatment for Macular Disease.</article-title>
            <source>Ophthalmol Ther</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>429</fpage>
            <pub-id pub-id-type="pmid">34213757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Predicted biological activity of intravitreal VEGF Trap.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2008</year>
            <month>May</month>
            <volume>92</volume>
            <issue>5</issue>
            <fpage>667</fpage>
            <page-range>667-8</page-range>
            <pub-id pub-id-type="pmid">18356264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Formica</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Awde Alfonso</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Palma</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology.</article-title>
            <source>Pharmacol Res Perspect</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>e00723</fpage>
            <pub-id pub-id-type="pmid">33694304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciombor</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Berlin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Aflibercept--a decoy VEGF receptor.</article-title>
            <source>Curr Oncol Rep</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>368</fpage>
            <pub-id pub-id-type="pmid">24445500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazzeri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ripandelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sartini</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Parravano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Varano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Desidero</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Orlandi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bocci</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.</article-title>
            <source>Angiogenesis</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>397</fpage>
            <page-range>397-432</page-range>
            <pub-id pub-id-type="pmid">26346237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uy</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Artiaga</surname>
                <given-names>JCM</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Two Different Intravitreal Injection Techniques.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2021</year>
            <volume>15</volume>
            <fpage>2383</fpage>
            <page-range>2383-2389</page-range>
            <pub-id pub-id-type="pmid">34135566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres-Costa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brand&#x000e3;o</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carneiro</surname>
                <given-names>&#x000c2;</given-names>
              </name>
              <name>
                <surname>Rosas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rocha-Sousa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Falc&#x000e3;o-Reis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Falc&#x000e3;o</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>600</fpage>
            <page-range>600-606</page-range>
            <pub-id pub-id-type="pmid">32019339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doshi</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Bakri</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal injection technique.</article-title>
            <source>Semin Ophthalmol</source>
            <year>2011</year>
            <month>May</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>104</fpage>
            <page-range>104-13</page-range>
            <pub-id pub-id-type="pmid">21609222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal Injection--Technique and Safety.</article-title>
            <source>Asia Pac J Ophthalmol (Phila)</source>
            <year>2015</year>
            <season>Nov-Dec</season>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>321</fpage>
            <page-range>321-8</page-range>
            <pub-id pub-id-type="pmid">26649760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iyer</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Albini</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Drug-related adverse effects of antivascular endothelial growth factor agents.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>191</fpage>
            <page-range>191-197</page-range>
            <pub-id pub-id-type="pmid">33770015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falavarjani</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
            </person-group>
            <article-title>Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.</article-title>
            <source>Eye (Lond)</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>787</fpage>
            <page-range>787-94</page-range>
            <pub-id pub-id-type="pmid">23722722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zografos</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wolin</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Calingaert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Hollis</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Schmidt-Ott</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Petraro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vassilev</surname>
                <given-names>ZP</given-names>
              </name>
            </person-group>
            <article-title>Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures.</article-title>
            <source>Pharmaceut Med</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>219</fpage>
            <page-range>219-233</page-range>
            <pub-id pub-id-type="pmid">31933286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peracha</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Anti-Vascular Endothelial Growth Factor Therapy in Pregnancy: What We Know, What We Don't Know, and What We Don't Know We Don't Know.</article-title>
            <source>Retina</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>8</issue>
            <fpage>1413</fpage>
            <page-range>1413-7</page-range>
            <pub-id pub-id-type="pmid">27388726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Ziv-Aflibercept</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>6</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">29999888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-Layana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Figueroa</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Araiz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ruiz-Moreno</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Ulla</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Arias-Barquet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.</article-title>
            <source>Drugs Aging</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>10</issue>
            <fpage>797</fpage>
            <page-range>797-807</page-range>
            <pub-id pub-id-type="pmid">26442858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avery</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Castellarin</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Steinle</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Dhoot</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Pieramici</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>See</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Couvillion</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nasir</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rabena</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Visich</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>98</volume>
            <issue>12</issue>
            <fpage>1636</fpage>
            <page-range>1636-41</page-range>
            <pub-id pub-id-type="pmid">25001321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avery</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Bakri</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Blumenkranz</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Brucker</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>D&#x002bc;Amico</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Dugel</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Jumper</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Liebmann</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>McCannel</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Mieler</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Ta</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal injection technique and monitoring: updated guidelines of an expert panel.</article-title>
            <source>Retina</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>34 Suppl 12</volume>
            <fpage>S1</fpage>
            <page-range>S1-S18</page-range>
            <pub-id pub-id-type="pmid">25489719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Estrada</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Maldonado</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mallipattu</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-200</page-range>
            <pub-id pub-id-type="pmid">30642877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmidt-Erfurth</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Korobelnik</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Simader</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Slakter</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vitti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berliner</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Soo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Anderesi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sowade</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Zeitz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Norenberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sandbrink</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heier</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.</article-title>
            <source>Ophthalmology</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>121</volume>
            <issue>1</issue>
            <fpage>193</fpage>
            <page-range>193-201</page-range>
            <pub-id pub-id-type="pmid">24084500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Oliveira Dias</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Badar&#x000f3;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Novais</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Colicchio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chiarantin</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Matioli</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Verna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Penha</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Barros</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Farah</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Preclinical investigations of intravitreal ziv-aflibercept.</article-title>
            <source>Ophthalmic Surg Lasers Imaging Retina</source>
            <year>2014</year>
            <season>Nov-Dec</season>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>577</fpage>
            <page-range>577-84</page-range>
            <pub-id pub-id-type="pmid">25423640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guest</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Malbin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Parendo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okeagu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>BX</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Accuracy of intravitreal injection volume for aflibercept pre-filled syringe and BD Luer-Lok one-milliliter syringe.</article-title>
            <source>Int J Retina Vitreous</source>
            <year>2022</year>
            <month>Apr</month>
            <day>05</day>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <pub-id pub-id-type="pmid">35382900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144967.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peden</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Su&#x000f1;er</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Hammer</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Grizzard</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.</article-title>
            <source>Ophthalmology</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>122</volume>
            <issue>4</issue>
            <fpage>803</fpage>
            <page-range>803-8</page-range>
            <pub-id pub-id-type="pmid">25596618</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
